Journal
/
/
建立双抗 EGFR-使用 tki 药物治疗和满足使用 tki 药物治疗在肺腺癌细胞体外与 2 步剂量升级程序
JoVE Journal
Cancer Research
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Cancer Research
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
DOI:

09:38 min

August 11, 2017

, , ,

Chapters

  • 00:05Title
  • 00:30Determining Initial Gefitnib Concentration Using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenylterazolium Bromide (MTT) Assay
  • 02:15Continuous Stepwise Dose-escalation of Gefitnib Treatment of PC-9 Cells
  • 03:31Determine Initial Concentration of PHA665752 Using the MTT Assay
  • 06:37Results: Two-step Dose-escalation Procedure to Establish Dual Resistance to EGFT-TKI and MET-TKI
  • 08:21Conclusion

Summary

Automatic Translation

在体外建立双抗 EGFR-使用 tki 药物治疗和癌症细胞中大都会使用 tki 药物治疗方法。此方法是用于开发陈列尽管大都会放大 EGFR-使用 tki 药物治疗治疗疾病进展的 EGFR 突变,患者的治疗方法。它也可以修改为针对其他分子的抑制剂。

Related Videos

Read Article